4-amino-6-(1-benzofuran-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one | 1415344-39-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 4-amino-6-(1-benzofuran-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one
• 英文别名: 4-Amino-6-(1-benzofuran-5-yl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5-one
• CAS: 1415344-39-6
• 化学式: C₁₅H₁₂N₄O₃
• 分子量: 296.285
• InChiKey: ZYAZYCCGJXSNGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  94.5
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS EN TANT QU'INHIBITEURS DE DIACYLGLYCÉROL ACYLTRANSFÉRASE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2012162129A1

  公开（公告）日：2012-11-29

  This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.

  这项发明涉及一种新型化合物，它们是酰辅酶A：二酰基甘油酰基转移酶1（DGAT-1）的抑制剂，以及含有它们的药物组合物，它们的制备方法，以及它们在治疗中的应用，用于预防或治疗与DGAT-1功能障碍相关的疾病，或者调节DGAT-1活性可能具有治疗益处的疾病，包括但不限于肥胖，与肥胖相关的疾病，高三酰甘油血症，高脂蛋白血症，乳糜微粒血症，脂质代谢异常，非酒精性脂肪肝炎，糖尿病，胰岛素抵抗，代谢综合征，丙型肝炎病毒感染，痤疮或其他皮肤疾病。
• NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS
  申请人：GlaxoSmithKline Intellectual Property (No.2) Limited

  公开号：US20140378434A1

  公开（公告）日：2014-12-25

  This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.

  本发明涉及一种新型化合物，其为酰基辅酶A: 二酰基甘油酰基转移酶1（DGAT-1）的抑制剂，含有它们的制药组合物，制备它们的过程以及它们在预防或治疗与DGAT-1功能障碍相关的疾病或调节DGAT-1活性可能具有治疗益处的治疗中的使用，包括但不限于肥胖症，肥胖相关疾病，高三酰甘油血症，高脂蛋白血症，乳糜微粒血症，脂质代谢异常，非酒精性脂肪性肝炎，糖尿病，胰岛素抵抗，代谢综合症，丙型肝炎病毒感染以及痤疮或其他皮肤疾病。
• Novel Compounds as Diacylglycerol Acyltransferase Inhibitors
  申请人：Qin Donghui

  公开号：US20140080809A1

  公开（公告）日：2014-03-20

  This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.

  本发明涉及一种新型化合物，它们是酰基辅酶A：二酰基甘油酰基转移酶1（DGAT-1）的抑制剂，以及包含它们的制药组合物、它们的制备过程，以及它们在预防或治疗与DGAT-1功能障碍相关的疾病或调节DGAT-1活性可能具有治疗益处的疾病中的使用，包括但不限于肥胖症，肥胖相关疾病，高甘油三酯血症，高脂蛋白血症，乳糜微粒血症，脂质代谢异常，非酒精性脂肪肝，糖尿病，胰岛素抵抗，代谢综合征，丙型肝炎病毒感染以及痤疮或其他皮肤疾病。
• US8859536B2
  申请人：——

  公开号：US8859536B2

  公开（公告）日：2014-10-14
• US9040517B2
  申请人：——

  公开号：US9040517B2

  公开（公告）日：2015-05-26